75% of Men Not Receiving Appropriate Treatment for Erectile Dysfunction

75% of Men Not Receiving Appropriate Treatment for Erectile Dysfunction

28th Annual EAU CongressAt the 28th Annual EAU Congress, held in mid- March 2013 some startling statistic regarding men suffering from Erectile Dysfunction were revealed. Known also as ED, Erectile Dysfunction plagues almost 88 million men worldwide.  Shocking numbers from a large clinical study of a subset of these patients, specifically a little over 6 million men, showed that just about three-fourths of these men receive no treatment.  This clinical study was the largest one to date of patients with ED, and the comprehensive nature of it is certainly telling. The number of men affected by Erectile Dysfunction is growing, and greater research, development and medical intervention is clearly needed to effectively treat this patient population. The patent for GlaxoSmithKline’s Levitra expires on October 31, 2018, leaving a crucial void for generic options of Vardenafil needing to be filled.

VardenafilVardenafil Hydrochloride CAS# 224785-91-5,  is a phosphodiesterase inhibitor and is prescribed to treat impotence or erectile dysfunction (ED) in men. Vardenafil works by helping to relax muscles and increase the blood flow into the penis for men during sexual activity. This increase in blood flow helps most men to achieve and maintain an erection. Only one dose of vardenafil should be taken in a 24 hour period, and there are few adverse effects, such as dizziness and an upset stomach. Patients taking nitrate medications, such as nitroglycerin, should not be administered with vardenafil, as this drug combination can cause a sudden and dangerous drop in blood pressure. Vardenafil may be taken about 60 minutes before sexual activity, but no more than one time in a 24 hour period.

Men who receive the diagnosis of Erectile Dysfunction will typically have a documented erection failure rate of 50 percent or more. There are many causes of ED in men, including serious diseases, such as atherosclerosis  or venous leakage. Underlying causes of ED must be determined before pharmaceutical treatment is given. More common factors contributing to ED in men include stress, performance anxiety, depression, side effects of other medications and concern about injury to the penis.

LGM Pharma can provide Vardenafil Base and Vardenafil Hydrochloride for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service